What do systematic reviews say?

Methylnaltrexone vs placebo

Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).

• Mu‐opioid antagonists for opioid‐induced bowel dysfunction in people with cancer and people receiving palliative care 2022 · Cochrane Headline outcomes only
  RR 0.59 [0.38, 0.93]
  2 studies · 364 participants
  Low